The Harms of Antipsychotic Drugs: Evidence from Key Studies
This safety assessment provides a detailed analysis of key studies and focuses on the six most widely used antipsychotic drugs. Lines of evidence include mechanisms of action, short-term treatment of psychosis, relapse prevention, early intervention in schizophrenia, long-term comparisons between first- and second-generation agents, and flexible treatment algorithms. Despite the diversity of study settings, several common features were seen. All the agents obstruct normal signaling through widely dispersed dopamine D2 receptors. Treatment failure or psychosis relapse was the most frequent outcome in most key studies, ranging from 38 to 93%. High discontinuation rates caused most trials to fail to demonstrate a substantial treatment benefit, or difference from an active comparator. Assessment of harm to the extrapyramidal motor system was confounded because of extensive neurological impairment from previous antipsychotic drug treatment measured at baseline, abrupt discontinuation effects, and high rates of concomitant medications to manage drug adverse effects. Claims that second-generation antipsychotic drugs have safety advantages over classical neuroleptic drugs and prevent relapse were not supported in these key studies. The extent of injury to and impairment of multiple body systems caused by antipsychotic drugs shows the need for a scientific, clinical, and regulatory reappraisal of the appropriate use of these agents.
KeywordsRisperidone Olanzapine Quetiapine Antipsychotic Drug Aripiprazole
The authors thank Sonal Singh of the Johns Hopkins University School of Medicine for his comments and review of an earlier version of this manuscript.
Compliance with Ethical Standards
No funding was used in the preparation of this study.
Conflict of interest
Thomas J. Moore and Curt D. Furberg declare that they have no conflicts of interest relevant to this study.
This analysis relies exclusively on published or publicly available data and is therefore exempt from institutional review board requirements.
- 1.WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) classification system: structure and principles. WHOCC. 2011. http://www.whocc.no/atc/structure_and_principles/. Accessed 9 Jul 2016.
- 2.Brunton L, Chabner B, Knollman B. Goodman and Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Education/Medical; 2011.Google Scholar
- 3.Baldessarini RJ, Cole JO, Davis JM, Gardos G. Task Force Report 18: tardive dyskinesia. Report of the American Psychiatric Association Task Force on late neurological effects of antipsychotic drugs. Washington, DC: American Psychiatric Association; 1980.Google Scholar
- 4.Lawrence RE, First MB, Lieberman JA. Schitzophrenia and other psychoses. Psychiatry Vol. 2. 4th ed. West Sussex: Wiley-Blackwell; 2015.Google Scholar
- 11.Sadock BJ, Sadock VA. Kaplan and Sadock’s synopsis of psychiatry: behavioral sciences/clinical psychiatry. 11th ed. Philadelphia (PA): LWW; 2014.Google Scholar
- 12.Kapur S, Remington G, Zipursky RB, et al. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 1995;57:PL103–7.Google Scholar
- 16.Mosholder AD. Review and evaluation of clinical data NDA 20-639 quetiapine fumarate seroquel. Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 1997.Google Scholar
- 17.Chuen MM, Dubitsky GM. Clinical review NDA 22-047 quetiapine fumarate sustained-released tablets. Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 2007.Google Scholar
- 18.Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988;24:97–9.Google Scholar
- 20.Simpson GM, Angus JWS. Modified Simpson-Angus Scale. Acta Psychiatr Scand. 1970;212(Suppl. 44):9–11.Google Scholar
- 22.Tarsy D, Parihar R. Tardive syndromes: clinical manifestations, pathophysiology, and epidemiology. Cambridge: Cambridge University Press; 2015. p. 195.Google Scholar
- 24.Hoberman D. Statistical review and evaluation: NDA 20-639 seroquel (quetiapine). Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 1997.Google Scholar
- 25.Rexulti®. Brexpiprazole tablet prescribing information [package insert]. Tokyo: Otsuka America Pharmaceutical, Inc.; 2015.Google Scholar
- 26.Farchione T. Clinical review Brexpiprazole (Rexulti) NDA 205422. Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 2015.Google Scholar
- 27.Kordzakhia G. Statistical review and evaluation: brexipiprazole NDA # 205, 422/O-2. Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 2015.Google Scholar
- 30.Chen Y-F. Statistical review and evaluation Abilitat (aripiprazole) tabs. Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; 2002.Google Scholar
- 33.Jansen LH, Hojyo-Tomoko LH, Kligman LH. Editorial: drugs causing weight gain. BMJ. 1974;1:168.Google Scholar
- 39.Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079–87.CrossRefPubMedGoogle Scholar